Funding

This article was sponsored by Janssen. Medical writing and editorial support were funded by Janssen.

Competing interests

LP reports consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Samsung-Bioepis, and UCB; payment or honoraria from Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from Janssen and UCB; grants received from Abbvie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB; and a non-financial relationship with the International Psoriasis Council. AC reports consulting fees from AbbVie and UCB; payment or honoraria from AbbVie, Almirall, Amgen, Galderma, Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from AbbVie; and participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB. EMGJdJ reports receiving research grants from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, and UCB; and has acted as a consultant, paid speaker, and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Galapagos, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, Sanofi, and UCB. TT reports consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sandoz, and Sanofi; support for attending meetings and/or travel from AbbVie, Almirall, Janssen, Leo Pharma, MSD, Novartis, Pfizer, and Sanofi; and participation on a Data Safety Monitoring Board and/or Advisory Board for Samsung-Bioepis. RBW reports consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB; and grants received from AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB. RW holds stock at Johnson & Johnson and was a full-time employee of Janssen at the time of the study. SW is a full-time employee of and owns stock at Janssen. PG is a full-time employee at Janssen. TG is a full-time employee at Janssen. MJ holds stocks at Johnson & Johnson and is a full-time employee at Janssen. JB is a full-time employee at Janssen. CC reports consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB; payment or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB; participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, MSD, Novartis, Pfizer, and UCB; grants received from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, and Pfizer; and leadership and/or fiduciary roles for the European Society for Dermatological Research and the Swiss Society for Dermatology and Venereology.

Ethics approval

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Given that this is a post-hoc analysis of the VOYAGE 1 clinical trial, ethical approval was not needed.

Consent to participate

Patients provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits of treatment.

Consent to publish

Not applicable.

Data availability statement

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Author contributions

LP, AC, TT, RBW, RW, SW, PG, TG, MJ, and CC contributed to conceptualization of the study; TT, RW, SW, PG, MJ, and CC contributed to the development and design of the methodology; TT, SW, and JB contributed to the data curation; TT, RW, and JB contributed to formal data analysis; SW, PG, and MJ provided funding acquisition and financial support for the project; LP, TT, PG, and CC conducted the research; RBW, SW, PG, MJ, and CC planned, directed, and coordinated research activity; PG provided resources and analysis tools; RW contributed to the programming and implementation of computer programs; AC, TT, RBW, SW, PG, and MJ provided supervision of the research, including mentorship; AC, TT, SW, PG, MJ, and JB provided validation of the results; LP, AC, TT, SW, MJ, JB, and CC contributed to data visualization and presentation; SW, PG, and TG contributed to writing the initial draft of the manuscript; LP, AC, EMGJdJ, TT, RBW, RW, SW, PG, TG, JB, and CC provided critical review at each stage the manuscript’s development. All authors approved the final version of the manuscript.

Code availability

Not applicable.